Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 22, n. 1, 2021. DOI: 10.7175/fe.v22i1.1499. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1499. Acesso em: 28 dec. 2025.